For information on any of the following cancer screenings, please call 1-800- ALEGENT (1-800-253-4368) or e-mail.
For Women
Breast Cancer Screening
The American Cancer Society recommends that:
- Women age 20-39 should have a clinical breast exam performed by a health care professional every three years. Monthly breast self-exam (BSE) is an option for women starting in their 20's
- Women age 40 and older should have an annual clinical breast exam by a health care professional and an annual mammogram.
- Discuss with your doctor your personal risk factors. Women at higher risk may need more frequent screening.
Cervical Cancer Screening
-
The schedule for cervical cancer screening now varies depending on a woman's age, when a woman begins having intercourse, the type of Pap test used (regular or liquid-based), her immune system health, if she has had consecutive normal Pap test results and whether or not she has had a hysterectomy. Consult your doctor to determine your cervical cancer screening needs.
For Men
Prostate Cancer Screening
- Men age 50 and older should talk with their health
care professional about having a prostate-specific antigen (PSA) blood
test and a digital rectal exam of the prostate gland every year. Factors to
consider include overall health and life expectancy.
- Men who are at high risk for getting prostate cancer (African Americans or men who have a history of prostate cancer in close family members) should consider beginning these tests at a younger age.
For Men and Women
The American Cancer Society's Screening Recommendations
Adults age 50 and older
Tests That Detect Adenomatous Polyps and Cancer
- Flexible sigmoidoscopy (FSIG) every 5 years, or
- Colonoscopy every 10 years, or
- Double contrast barium enema (DCBE) every 5 years, or
- CT colonography (CTC) every 5 years
Tests That Primarily Detect Cancer
- Annual fecal occult blood test (gFOBT) with high test sensitivity for cancer, or
- Annual fecal immunochemical test (FIT) with high test sensitivity for cancer, or
- Stool DNA test (sDNA), with high test sensitivity for cancer, interval uncertain